Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA, U6 small nuclear 792, pseudogene (RNU6-792P) is a member of the large family of U6 small nuclear RNA (snRNA) pseudogenes in the human genome. While the canonical U6 snRNA is a core component of the spliceosome where it plays an essential catalytic role in pre-mRNA splicing[1][3], pseudogenes such as RNU6-792P are the result of gene duplication or retrotransposition events that have accumulated mutations and lost the ability to produce functional U6 snRNA molecules[4][5]. U6-derived pseudogenes are prevalent in vertebrate genomes[3]. While most pseudogenes, including RNU6-792P, are generally considered non-functional ("dead" genes), emerging studies indicate that some pseudogenes can generate non-coding transcripts involved in *trans*-regulation of gene expression (e.g., “miRNA sponges” or sources of small interfering RNAs) or participate in epigenetic modulation[2][4]. However, there is no evidence that RNU6-792P is a therapeutic target, is directly associated with disease, or interacts with drugs. Pseudogenes generally do not encode proteins, nor do they possess the canonical regulatory or catalytic activity of their parental genes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 792, pseudogene (RNU6-792P).